KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBT Margin (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EBT Margin data on record, last reported at 17.4% in Q4 2025.

  • For Q4 2025, EBT Margin rose 516.0% year-over-year to 17.4%; the TTM value through Dec 2025 reached 8.6%, down 2016.0%, while the annual FY2025 figure was 14.71%, 2627.0% down from the prior year.
  • EBT Margin reached 17.4% in Q4 2025 per JAZZ's latest filing, up from 70.34% in the prior quarter.
  • Across five years, EBT Margin topped out at 22.33% in Q1 2021 and bottomed at 70.34% in Q2 2025.
  • Average EBT Margin over 5 years is 1.36%, with a median of 4.17% recorded in 2023.
  • Peak YoY movement for EBT Margin: surged 6147bps in 2021, then crashed -8381bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 5.0% in 2021, then plummeted by -600bps to 34.97% in 2022, then surged by 117bps to 6.08% in 2023, then skyrocketed by 101bps to 12.24% in 2024, then soared by 42bps to 17.4% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 17.4% in Q4 2025, 70.34% in Q2 2025, and 12.24% in Q4 2024.